Randomized Trialhigh evidence
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
The New England journal of medicine·April 18, 2024·PMID 38587233
Why it mattersThis is the first trial to demonstrate that a GLP-1 receptor agonist can specifically target obesity-related HFpEF in patients with type 2 diabetes, addressing a high symptom burden with no previously approved therapy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled